Metrics as of 10/13/2026, 06:31 PM (Berlin time), refresh in progress.
Scilex Holding Company
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to…
1D
+3.9%
1W
-26.5%
1M
-41.9%
6M
-50.9%
YTD
-76.1%
1Y
-80.3%
2Y
-89.5%
5Y
-99.2%
10Y
–
Next earnings date
02/12/2026 (in 46 days)
Volatility around earnings
~25% stronger price swings than usual
0
STRONG BUY
1
BUY
1
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 11/04/2025
P/E
-0.04
P/B
-0.07
EV/EBITDA
-0.33
RETURN ON EQUITY
36.8%
NET MARGIN
-1,485.2%
DEBT/EQUITY
-0.31
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
88.3%
FLOAT SHARES
7,500,542
AVG. DAILY VOLUME (30D)
40,208
SCLX Stock Acquisition JV LLC
Scilex Holding Co
Scilex Holding Company is a company in the Healthcare sector, Drug Manufacturers - General industry, headquartered in United States.
The CEO is Henry H. Ji, the company employs around 34 people.
The IPO was on 05/03/2021; the stock trades on NASDAQ under the ticker SCLX.
2 analysts rate the stock, the consensus is Buy (as of 11/04/2025).
This is an external assessment, not a statement by Market Jury.
The next earnings date is 02/12/2026.
Around past earnings, price swings were roughly 25% stronger than usual.
No, Scilex Holding Company currently does not pay a dividend.
Comparable stocks include Eli Lilly and Company, Johnson & Johnson, AbbVie, Merck &, Amgen, Gilead Sciences, Pfizer and Bristol-Myers Squibb Company.
Clicking "Analyze stock" lets five strategies assess Scilex Holding Company against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.